跳转至内容
Merck

CDS022173

Sigma-Aldrich

伊马替尼

别名:

4-(4-甲基哌嗪-1-甲基)-N-[4-甲基-3-[[4-(吡啶-3-基)嘧啶-2-基]氨基]苯基]苯甲酰胺, 4-[(4-甲基-1-哌嗪)甲基]-N-[4-甲基-3-[[4-(3-吡啶)-2-嘧啶]氨基]苯基]苯甲酰胺, CGP 57148, N-(4-甲基-3-((4-(吡啶-3-基)嘧啶-2-基)氨基)苯基)-4-((4-甲基哌嗪-1-基)甲基)苯甲酰胺, 甲磺酸伊马替尼

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C29H31N7O
分子量:
493.60
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:

描述

AldrichCPR

形狀

solid

SMILES 字串

O=C(C(C=C1)=CC=C1CN2CCN(C)CC2)NC3=CC(NC4=NC(C5=CN=CC=C5)=CC=N4)=C(C)C=C3

InChI

1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)

InChI 密鑰

KTUFNOKKBVMGRW-UHFFFAOYSA-N

基因資訊

一般說明

伊马替尼(Imatinib)是一种苯甲酰胺衍生物,用作特定酪氨酸激酶受体抑制剂。可抑制费城(Philadelphia, Ph)染色体异常导致的断裂点簇集区(BCR)-Abelson(ABL)融合蛋白。伊马替尼也用作强效的凋亡诱导剂和抗肿瘤药。

其他說明

请注意,Sigma-Aldrich将本品作为一系列特殊化学品的一部分提供给早期发现研究人员。Sigma-Aldrich不收集本品的分析数据。买方承担确认产品特性和/或纯度的责任。所有销售均为最终销售。

尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款,但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中,SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保,包括:(A)适销性担保;(B)特定用途适用性担保;或(C)未侵犯第三方知识产权担保。

象形圖

Health hazard

訊號詞

Danger

危險分類

Carc. 2 - Lact. - Muta. 2 - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sara D'Aronco et al.
European journal of mass spectrometry (Chichester, England), 22(5), 217-228 (2016-11-25)
Drug levels in patients' bloodstreams vary among individuals and consequently therapeutic drug monitoring (TDM) is fundamental to controlling the effective therapeutic range. For TDM purposes, different analytical approaches have been used, mainly based on immunoassay, liquid chromatography- ultraviolet, liquid chromatography-mass
Fengling Wang et al.
Anti-cancer drugs, 30(2), 159-166 (2018-11-14)
The Bcr/Abl kinase is an oncogenic fusion protein that plays a central role in the pathogenesis of chronic myeloid leukemia (CML). Some small-molecule kinase inhibitors such as imatinib were developed in the treatment of CML; however, resistant to imatinib is
Xiaohui Si et al.
Oncotarget, 7(47), 78095-78109 (2016-11-02)
Leukemia stem cells (LSCs) can resist available treatments that results in disease progression and/or relapse. To dissect the microRNA (miRNA) expression signature of relapse in acute myeloid leukemia (AML), miRNA array analysis was performed using enriched LSCs from paired bone
Laurent L Reber et al.
PloS one, 12(10), e0185704-e0185704 (2017-10-06)
Gouty arthritis is caused by the deposition of monosodium urate (MSU) crystals in joints. Despite many treatment options for gout, there is a substantial need for alternative treatments for patients unresponsive to current therapies. Tyrosine kinase inhibitors have demonstrated therapeutic
Doing evidence-based medicine? How NHS managers ration high-cost drugs.
David Hughes et al.
Social science & medicine (1982), 235, 112304-112304 (2019-07-16)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门